

10628309

=> d his

(FILE 'HOME' ENTERED AT 15:43:59 ON 08 SEP 2004)

FILE 'REGISTRY' ENTERED AT 15:44:12 ON 08 SEP 2004

L1 STRUCTURE UPLOADED

L2 9 S L1

FILE 'CAPLUS' ENTERED AT 15:44:44 ON 08 SEP 2004

S L1

FILE 'REGISTRY' ENTERED AT 15:44:47 ON 08 SEP 2004

L3 9 S L1

FILE 'CAPLUS' ENTERED AT 15:44:47 ON 08 SEP 2004

L4 7 S L3





FILE 'REGISTRY' ENTERED AT 15:45:11 ON 08 SEP 2004

L5 380 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 15:45:26 ON 08 SEP 2004

L6 22 S L5

=>



chain nodes :

7 9 10 25 27 28 29 30

ring nodes :

1 2 3 4 5 6 11 12 13 14 15 16 17 18 19 20 21

chain bonds :

3-9 6-7 7-10 7-25 18-27 18-28 20-29 20-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-15 12-13 13-14 14-15 16-17 16-21 17-18 18-19
19-20 20-21

exact/norm bonds :

3-9 6-7 7-10 7-25 11-12 11-15 12-13 13-14 14-15 16-17 16-21 17-18 18-19 19-20
20-21

exact bonds :

18-27 18-28 20-29 20-30

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 :

G1:C,S,N

G2:[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 25:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS

10628309

=> d bib abs hitstr 1-22

L6 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:303271 CAPLUS
DN 141:54509
TI N,N-Dialkyl-4-[(8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamides,
potent, selective δ opioid agonists
AU Carson, John R.; Coats, Steven J.; Codd, Ellen E.; Dax, Scott L.; Lee,
Jung; Martinez, Rebecca P.; Neilson, Lou Anne; Pitis, Philip M.; Zhang,
Sui-Po
CS Drug Discovery, Johnson and Johnson Pharmaceutical Research and
Development, LLC, Spring House, PA, 19477-0776, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2109-2112
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB A series of N,N-dialkyl-4-(9-aryltropanylidene)methyl)benzamides, e.g. I,
was prepared. The lead compds., II (R = H) and II (R = allyl), exhibited
extremely high affinity for the δ opioid receptor with excellent
selectivity vs. the μ opioid receptor. They were full agonists at the
 δ opioid receptor, as assessed by stimulation of GTPyS
binding, and displayed antinociceptive activity.


IT 209902-09-0 229477-67-2 287720-75-6

287720-76-7

RL: PAC (Pharmacological activity); BIOL (Biological study)
(N,N-Dialkyl-4-[(8-azabicyclo[3.2.1]oct-3-
ylidene)phenylmethyl]benzamides as potent and selective δ opioid
agonists)


RN 209902-09-0 CAPLUS

CN Benzamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)- (9CI) (CA INDEX
NAME)



RN 229477-67-2 CAPLUS


CN Benzamide, N,N-diethyl-4-[phenyl[1-(2-propenyl)-4-piperidinyl]amino]-
(9CI) (CA INDEX NAME)



RN 287720-75-6 CAPLUS


CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-ylphenylamino]-N,N-diethyl-
(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 287720-76-7 CAPLUS
 CN Benzamide, N,N-diethyl-4-[phenyl[(3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:542815 CAPLUS
 DN 140:94567
 TI Thermodynamic and adsorption properties of semiinterpenetrating polymer networks based on polybenzimidazoles and polyaminoimide resin
 AU Lenskaya, E. V.; Zheivot, V. I.; Mogonov, D. M.
 CS Baikal Institute of Nature Management, Siberian Branch of the Russian Academy of Sciences, Ulan-Ude, 670047, Russia
 SO Russian Chemical Bulletin (Translation of Izvestiya Akademii Nauk, Seriya Khimicheskaya) (2003), 52(5), 1083-1093
 CODEN: RCBUEY; ISSN: 1066-5285
 PB Kluwer Academic/Consultants Bureau
 DT Journal
 LA English
 AB Thermodyn. characteristics of adsorption of organic compds. on semi-interpenetrating polymer networks of a polybenzimidazole and a polyamine-polyimide resin of different compns. were studied using inverse gas chromatog. Specific retention vols. of alkanes, aromatic hydrocarbons, ethers, ketones, alcs., nitrogen-containing compds. and halogen-containing compds., changes in differential molar internal energy, entropy and Helmholtz potential were determined Contributions of the mol. fragments to heat of adsorption were calculated Unlike graphitized carbon black (nonspecific adsorbent), the semi-interpenetrating polymer networks and starting polymers were characterized by both nonspecific and specific interactions (electron-donating and electron-accepting). The difference in the thermodyn. characteristics of adsorption on the semi-interpenetrating polymeric networks of different compns. was shown to be dictated by the size and geometry of interphase regions.
 IT 643066-34-6
 RL: POF (Polymer in formulation); PRP (Properties); USES (Uses) (thermodyn. and adsorption properties of semi-interpenetrating polymer networks based on polybenzimidazoles and polyamine-polyimides)
 RN 643066-34-6 CAPLUS
 CN Poly[(2,5-dioxo-3,1-pyrrolidinediyl)-1,4-phenylenemethylene-1,4-phenylene(2,5-dioxo-1,3-pyrrolidinediyl)imino-1,4-phenylenemethylene-1,4-phenyleneimino], α -[[4-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl]methyl]phenyl]amino]- ω -[1-[4-[[4-[3-[[4-[[4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl]methyl]phenyl]amino]-2,5-dioxo-1-pyrrolidiny]phenyl]methyl]phenyl]-2,5-dioxo-3-pyrrolidiny]]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



PAGE 1-C



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:202634 CAPLUS
DN 138:238191
TI Preparation of 1-[1-(pyrimidin-5-ylcarbonyl)piperidin-4-yl]piperidin-4-
amines as CCR5 antagonists
IN Palani, Anandan; Miller, Michael W.; Scott, Jack D.
PA Schering Corporation, USA
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020716	A1	20030313	WO 2002-US27389	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

10628309

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG

US 2004010008 A1 20040115 US 2002-229466 20020828
EP 1421075 A1 20040526 EP 2002-766142 20020828

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

US 2004092745 A1 20040513 US 2003-628933 20030729
US 2004092551 A1 20040513 US 2003-629466 20030729



PRAI US 2001-315683P P 20010829

US 2002-229466 A3 20020828

WO 2002-US27389 W 20020828

OS MARPAT 138:238191

GI



AB The title compds. [I; R1 = piperidinyl, Ph, etc.; R2 = CH2Ph, 4-pyridylmethyl, etc.; R3 = 4,6-dimethylpyrimidine-5-yl, Ph, etc.; R9, R10, B = H, alkyl, haloalkyl; A = H, alkyl, alkenyl] and their pharmaceutically acceptable salts, useful, alone or in combination with another agent, in the treatment of Human Immunodeficiency Virus (HIV), solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, were prepared E.g., a 6-step synthesis of II, starting from 4-hydroxypiperidine and N-Boc-4-piperidone, which showed IC50 of 1.7 nM in luciferase HIV replication assay, was given.


IT **501446-53-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-[1-(pyrimidin-5-ylcarbonyl)piperidin-4-yl]piperidin-4-amines as CCR5 antagonists)

RN 501446-53-3 CAPLUS

CN [1,4'-Bipiperidin]-4-amine, 1'-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-N-(4-ethylphenyl)-N-phenyl-4'-methyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:906156 CAPLUS
DN 138:4530
TI Preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid
receptor agonists for treating pain, anxiety or gastrointestinal disorders
IN Brown, William; Griffin, Andrew; Walpole, Christopher
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002094785	A1	20021128	WO 2002-SE957	20020516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200300526	A	20040216	EE 2003-526	20020516
EP 1395557	A1	20040310	EP 2002-733713	20020516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009665	A	20040420	BR 2002-9665	20020516
US 2004142966	A1	20040722	US 2003-477636	20031113
PRAI SE 2001-1773	A	20010518		
WO 2002-SE957	W	20020516		
OS CASREACT 138:4530; MARPAT 138:4530				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph, pyridyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl and pyridyl N-oxide], useful in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders, were prepared and formulated. Thus, reductive amination of the benzamide II (3-step synthesis given) with 3-furaldehyde in the presence of NaBH(OAc)₃ in 1,2-dichloroethane followed by hydrolysis of the resulting intermediate afforded I [R1 = 3-furyl]. The exemplified compds. I showed IC₅₀ of 0.4-1.155 nM against human δ receptor binding.

IT 477178-28-2P 477178-29-3P 477178-30-6P
477178-31-7P 477178-32-8P 477178-33-9P
477178-34-0P 477178-35-1P 477178-36-2P
477178-37-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)

RN 477178-28-2 CAPLUS


10628309

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-furanylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477178-29-3 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-30-6 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-thiazolylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-31-7 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

10628309




RN 477178-32-8 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-thienylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-33-9 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(4-pyridinylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-34-0 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-pyridinylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

10628309




RN 477178-35-1 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-thienylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477178-36-2 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-furanylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477178-37-3 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




IT 477178-39-5P 477178-40-8P 477178-41-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)
 RN 477178-39-5 CAPLUS
 CN Benzamide, 4-[(5-cyano-2-fluorophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-40-8 CAPLUS
 CN Benzamide, 4-[(5-cyano-2-fluorophenyl)-4-piperidinylamino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477178-41-9 CAPLUS
 CN Benzamide, 4-[(5-cyano-2-fluorophenyl)[1-(3-furanylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:906154 CAPLUS
DN 138:4529
TI Preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid
receptor agonists for treating pain, anxiety or gastrointestinal disorders
IN Brown, William; Griffin, Andrew; Walpole, Christopher
PA Astrazeneca Ab, Swed.
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094784	A1	20021128	WO 2002-SE955	20020516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EE 200300535	A	20040216	EE 2003-535	20020516
EP 1395556	A1	20040310	EP 2002-733711	20020516
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002009675	A	20040727	BR 2002-9675	20020516
US 2004142965	A1	20040722	US 2003-477633	20031113
PRAI SE 2001-1771	A	20010518		
WO 2002-SE955	W	20020516		
OS CASREACT 138:4529; MARPAT 138:4529				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph, pyridyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl, and pyridyl N-oxide], useful in therapy, in particular in the management of pain, anxiety or functional gastrointestinal disorders, were prepared and formulated. Thus, reductive amination of the benzamide II (multi-step synthesis given) with 2-pyridinecarboxaldehyde in the presence of NaBH(OAc)₃ in THF followed by hydrolysis of the intermediate afforded I [R1 = 2-pyridyl]. The exemplified compds. I showed IC₅₀ of 0.293-1.18 nM against human δ receptor binding.

IT 477178-98-6P 477178-99-7P 477179-00-3P
477179-01-4P 477179-02-5P 477179-03-6P
477179-04-7P 477179-05-8P 477179-06-9P

10628309

477179-07-0P 477179-08-1P 477179-09-2P


477179-10-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)


RN 477178-98-6 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477178-99-7 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477179-00-3 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-thienylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-01-4 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-thiazolylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)


10628309



RN 477179-02-5 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(3-thienylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-03-6 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-furanylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-04-7 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(3-furanylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

10628309




RN 477179-05-8 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-chlorophenyl)methyl]-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-06-9 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477179-07-0 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-fluorophenyl)methyl]-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-08-1 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(1H-pyrrol-2-ylmethyl)-4-


10628309

piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 477179-09-2 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477179-10-5 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-ethylphenyl)methyl]-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



IT 437986-95-3P 477179-11-6P 477179-12-7P


477179-15-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)

RN 437986-95-3 CAPLUS


CN Benzamide, 4-[[3-(cyanophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



10628309


RN 477179-11-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[bis(1-methylethyl)amino]carbonyl]phenyl](3-cyanophenyl)amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 477179-12-7 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)-4-piperidinylamino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 477179-15-0 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)[1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:906152 CAPLUS

DN 138:4528

TI Preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders

IN Brown, William; Griffin, Andrew; Walpole, Christopher

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094783	A1	20021128	WO 2002-SE945	20020516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EE 200300534 A 20040216 EE 2003-534 20020516
 EP 1395558 A1 20040310 EP 2002-736338 20020516
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2002009669 A 20040420 BR 2002-9669 20020516
 US 2004152731 A1 20040805 US 2003-477853 20031113
 PRAI SE 2001-1770 A 20010518
 WO 2002-SE945 W 20020516
 OS CASREACT 138:4528; MARPAT 138:4528
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph, pyridyl, thienyl, furanyl, imidazolyl, pyrrolyl, triazolyl, thiazolyl and pyridyl N-oxide], useful in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders, were prepared and formulated. Thus, reductive amination of the benzamide II (3-step synthesis given) with pyridine-2-carboxaldehyde in the presence of NaBH(OAc)₃ in THF followed by hydrolysis of the resulting intermediate afforded I [R1 = 2-pyridyl]. The exemplified compds. I showed IC₅₀ of 0.247-5.405 nM against human δ receptor binding.

IT 477178-74-8P 477178-75-9P 477178-76-0P

477178-77-1P 477178-78-2P 477178-79-3P

477178-80-6P 477178-81-7P 477178-82-8P

477178-83-9P 477178-84-0P 477178-85-1P


477178-86-2P 477178-87-3P 477179-42-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)

RN 477178-74-8 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-75-9 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-76-0 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-thienylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-77-1 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-furanylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-78-2 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-thienylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-79-3 CAPLUS

477170-75-5 CAS#200
CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-[(2,4-dichlorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-80-6 CAPLUS


47717-88-9 CASRN
 Benzamide, 4-[[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-thiazolylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-81-7 CAPLUS


NN 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-[(4-bromophenyl)methyl]-
 CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-[(4-bromophenyl)methyl]-
 4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-82-8 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(2-furanylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-83-9 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(4-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-84-0 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-[(4-chlorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



10628309


RN 477178-85-1 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(3-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-86-2 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-87-3 CAPLUS


CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477179-42-3 CAPLUS

CN Benzamide, 4-[[5-(aminocarbonyl)-2-fluorophenyl][1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




IT 477178-88-4P 477178-89-5P 477178-90-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)


RN 477178-88-4 CAPLUS

CN Benzamide, 4-[(5-cyano-2-fluorophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-89-5 CAPLUS

CN Benzamide, 4-[(5-cyano-2-fluorophenyl)-4-piperidinylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-90-8 CAPLUS

CN Benzamide, 4-[(5-cyano-2-fluorophenyl)[1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:906151 CAPLUS
DN 138:4527
TI Preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid
receptor agonists for treating pain, anxiety or gastrointestinal disorders
IN Brown, William; Griffin, Andrew; Walpole, Christopher
PA Astrazeneca AB, Swed.
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002094782	A1	20021128	WO 2002-SE944	20020516
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EE 200300554	A	20040216	EE 2003-554	20020516
	EP 1395555	A1	20040310	EP 2002-733702	20020516
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2002009670	A	20040420	BR 2002-9670	20020516
PRAI	SE 2001-1769	A	20010518		
	WO 2002-SE944	W	20020516		
OS	CASREACT 138:4527; MARPAT 138:4527				
GI					

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; R1 = (un)substituted Ph, pyridyl, pyrrolyl, thienyl, furanyl, imidazolyl, triazolyl, and pyridyl N-oxide], useful in therapy, in particular in the management of pain, anxiety and functional gastrointestinal disorders, were prepared and formulated. Thus, reductive amination of the benzamide II (3-step synthesis given) with 2,4-dichlorobenzaldehyde in the presence of $\text{NaBH}(\text{OAc})_3$ in THF followed by hydrolysis of the intermediate afforded I [R1 = 2,4- $\text{Cl}_2\text{C}_6\text{H}_3$]. The exemplified compds. I showed IC_{50} of 0.155-1.47 nM against human δ receptor binding.

IT 477178-42-0P 477178-43-1P 477178-44-2P
477178-45-3P 477178-46-4P 477178-47-5P
477178-48-6P 477178-49-7P 477178-50-0P
477178-51-1P 477178-52-2P 477178-53-3P
477178-54-4P 477178-55-5P 477178-56-6P
477178-57-7P 477178-58-8P 477178-59-9P
477178-60-2P 477178-61-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


10628309

(Uses)

(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid receptor agonists for treating pain, anxiety or gastrointestinal disorders)


RN 477178-42-0 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-43-1 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(2,4-dichlorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-44-2 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(4-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-45-3 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-46-4 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-furanylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-47-5 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-bromophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-48-6 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-49-7 CAPLUS


10628309

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(3-furanylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-50-0 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(3-thienylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-51-1 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-52-2 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-53-3 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-thiazolylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-54-4 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(2-thienylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-55-5 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(3-pyridinylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



10628309


RN 477178-56-6 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-chlorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-57-7 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-58-8 CAPLUS


CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-methoxyphenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-59-9 CAPLUS

CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-[(4-fluorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)


10628309



RN 477178-60-2 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 477178-61-3 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-((1-methyl-1H-pyrrol-2-yl)methyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




IT 437986-94-2P 477178-63-5P 477178-64-6P
477178-67-9P 477178-68-0P 477178-69-1P
477178-70-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of 4-[phenyl(piperidin-4-yl)amino]benzamides as δ opioid
receptor agonists for treating pain, anxiety or gastrointestinal
disorders)
RN 437986-94-2 CAPLUS
CN Benzamide, 4-[[3-(aminocarbonyl)phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-
diethyl- (9CI) (CA INDEX NAME)

10628309




RN 477178-63-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[(3-cyanophenyl)[4-[(diethylamino)carbonyl]phenyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 477178-64-6 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)-4-piperidinylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-67-9 CAPLUS


CN Benzamide, 4-[[3-(1,3-dioxolan-2-yl)phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 477178-68-0 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-formylphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

10628309




RN 477178-69-1 CAPLUS

CN Benzoic acid, 3-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 477178-70-4 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)[1-[(2,4-dichlorophenyl)methyl]-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:793604 CAPLUS

DN 137:310816

TI Preparation of bipiperidyl-derivatives and their use as chemokine receptors inhibitors

IN Albert, Rainer; Bruns, Christian; Nuninger, Francois; Streiff, Markus; Thoma, Gebhard; Zerwes, Hans-Guenter

PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.

SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2




DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002081449	A1	20021017	WO 2002-EP3871	20020408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
EP 1379504	A1	20040114	EP 2002-730122	20020408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008741	A	20040622	BR 2002-8741	20020408

JP 2004525174	T2	20040819	JP 2002-579437	20020408
US 2004142920	A1	20040722	US 2003-472653	20030922
NO 2003004324	A	20030926	NO 2003-4324	20030926
PRAI GB 2001-8876	A	20010409		
WO 2002-EP3871	W	20020408		
OS MARPAT 137:310816				
GI				



AB Piperidine derivs. I [X = bond, CH₂, CH₂CH₂, CHR₉, CO, O, NH, NR₉; R₁ = R₁₀- and/or R₁₁-substituted Ph, heteroaryl, heteroaryl N-oxide, naphthyl; R₂ = R₁, R₁₀- and/or R₁₁-substituted fluorenyl or R₁₀-substituted C1-6-alkyl, C2-6-alkenyl, C3-6-cycloalkyl, adamantyl, C4-8-cycloalkenyl; R₃ = R₂; R₁XNR₃ = optionally R₁₀-substituted Z; A = CH₂, NH, NR₉, S, SO, SO₂, O; n = 0 - 2; R₄, R₆ = R₅, CN, OH, OR₉, F, Cl, Br, I; R₅, R₇ = H, C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, Ph, CH₂Ph, heteroaryl; R₈ = H, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, CN, CH₂NH₂, CH₂NHR₉, CH₂N(R₉)₂, CH₂NHCOR₉, CH₂NR₉COR₉, CH₂NHCONHR₉, CH₂NR₉CONHR₉, CH₂NR₉CON(R₉)₂, CH₂NHCO₂R₉, CH₂NR₉CO₂R₉, CH₂NHSO₂R₉, CH₂N(SO₂R₉)₂, CH₂NR₉SO₂R₉; R₉ = C1-6-alkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-alkynyl, Ph, CH₂Ph, heteroaryl, CF₃] and their pharmaceutically acceptable salts, have interesting pharmaceutical properties, e.g., as CCR5 inhibitors. Piperidine derivs. I [R₁₀ = C1-6-alkyl, C1-6-hydroxyalkyl, C2-6-alkoxyalkyl, C1-6-haloalkyl, C3-6-cycloalkyl, C2-6-alkenyl, C2-6-cycloalkenyl, C2-6-alkynyl, Ph, heteroaryl, heteroaryl N-oxide, F, Cl, Br, I, OH, OR₉, CONH₂, CONHR₉, CON(R₉)₂, OC(:O)R₉, OCO₂R₉, OC(:O)NHR₉, OC(:O)NHR₉, OC(:O)N(R₉)₂, OSO₂R₉, CO₂H, CO₂R₉, CF₃, CHF₂, CH₂F, CN, NO₂, NH₂, NHR₉, N(R₉)₂, NHCOR₉, NR₉COR₉, NHCONHR₉, NHCONH₂, NR₉CONHR₉, NR₉CON(R₉)₂, NHCO₂R₉, NR₉CO₂R₉, NHSO₂R₉, N(SO₂R₉)₂, NR₉SO₂R₉, SiMe₃, B(OCMe₃); R₁₁ = two adjacent substituents which form an annulated 4 - 7 membered ring containing up to two heteroatoms of the group N, O, S; Y = bond, CO, COCH₂, SO, SO₂, CS, CH₂, C(CH₂CH₂), CHR₅, C(R₄)₂] have interesting pharmaceutical properties, e.g., their use as chemokine receptors inhibitors. A process for the preparation of I comprises; (a) amidating I (YR₂ = H) with R₂Y'A' [Y' = CO, COCH₂, SO, SO₂]; A' = leaving group, e.g., Cl, Br, OH; (b) reductive amidation of I (YR₂ = H); or (c) reacting I (XRI = H) with R₁X"-halogen (X" = CH₂, CHR₉). Thus, bipiperidinylbenzamide II (Y = CO, R₂ = C₆H₃Me₂-2,6) was prepared from bipiperidinamine II (Y = bond, R₂ = H) and 2,6-Me₂C₆H₃COCl in DMF containing EtN(CHMe₂)₂ and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate. Bipiperidinamines I were tested as chemokine receptor inhibitors [IC₅₀ = 2 - 3 nM vs. [I-125]MIP-1α binding to human CCR5 membrane for I (R₁ = R₃ = Ph, R₂ = C₆H₄Me₂-2,6, R₄ - R₇ = H, R₈ = Me, X = CH₂, Y = C:O); IC₅₀ = 10 μM vs. Ca²⁺ mobilization for II; chemotaxis by I in presence of MIP-1α, IC₅₀ = ≤ 1 μM].


IT 470689-70-4P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bipiperidinyl-derivs. and their use as chemokine receptors inhibitors)

RN 470689-70-4 CAPLUS


CN 1,4'-Bipiperidine, 1'-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4'-methyl-4-[phenyl[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:632801 CAPLUS
DN 137:169426
TI Preparation of 4-(diarylamino)piperidines as δ -opioid receptor agonists/antagonists.
IN Carson, John R.; Susan, Carmosin Richard J.; Fitzpatrick, Louis J.; Reitz, Allen B.; Jetter, Michele C.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6436959	B1	20020820	US 1998-220189	19981223
PRAI	US 1998-220189		19981223		
OS	MARPAT 137:169426				
GI					



I

AB Title compds. [I; Ar = Ph, naphthyl; R1, R2 = H, alkyl, (substituted) Ph, PhCH2; R1R2N = pyrrolidinyl, morpholinyl, piperidinyl, hexamethyleneiminy; R3-R5 = H, alkyl; R6 = H, alkyl, cycloalkylalkyl, alkenyl, alkoxyalkyl, (substituted) thienylalkyl, furylalkyl, pyrrolylalkyl, oxazolylalkyl, etc.; R7 = 0-3 of OH, halo, alkyl, alkoxy, acyl, acyloxy, cyano, amino, acylamino, alkylthio, alkylsulfonyl, CF3, OCF3, etc.; R8 = 0-2 of halo, alkyl, alkoxy, CF3], were prepared Thus, N-(3-methoxyphenyl)-1-propyl-4-piperidinamine (preparation given), N,N-diethyl-4-bromobenzamide, tris(dibenzylideneacetone)dipalladium(0), (R)-(+)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl and NaOCMe3 in PhMe were heated at 110° under Ar in a pressure vessel for 16 h to give 53% N,N-diethyl-4-[3-methoxyphenyl(1-propylpiperidin-4-yl)amino]benzamide fumarate (1:1). The latter gave 97% displacement of [3H]-bremazocine from δ -opioid receptors.

IT 209902-03-4P 229478-69-7P 229478-70-0P
229478-72-2P 229478-73-3P 229478-81-3P
229478-82-4P 229478-88-0P 229478-89-1P
229478-90-4P 229478-91-5P 229478-92-6P
229478-94-8P 229478-95-9P 229478-96-0P
229478-98-2P 229478-99-3P 229479-00-9P
229479-01-0P 229479-02-1P 229479-03-2P
229479-04-3P 229479-05-4P 229479-06-5P
229479-07-6P 229479-09-8P 229479-10-1P
229479-11-2P 229479-12-3P 229479-13-4P


229479-14-5P 229479-15-6P 229479-16-7P
 229479-17-8P 229479-18-9P 229479-19-0P
 229479-21-4P 229479-22-5P 229479-23-6P
 229479-24-7P 229479-25-8P 229479-26-9P
 229479-27-0P 229479-28-1P 229479-29-2P
 229479-30-5P 229479-31-6P 229479-32-7P
 229479-33-8P 229479-34-9P 229479-35-0P
 229479-37-2P 229479-39-4P 229479-40-7P
 229479-41-8P 229479-45-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4-(diarylamino)piperidines as δ -opioid receptor
 agonists/antagonists)


RN 209902-03-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-4-piperidinyl]amino]-
 (9CI) (CA INDEX NAME)




RN 229478-69-7 CAPLUS

CN Benzamide, 4-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinyl]phenylamino]-
 N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-70-0 CAPLUS

CN Benzamide, 4-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinyl](3-
 fluorophenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 229478-72-2 CAPLUS

CN Benzamide, 4-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-piperidinyl]phenylamino]-
 N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-73-3 CAPLUS

CN Benzamide, 4-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-piperidinyl](3-


10628309

methoxyphenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-81-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1-[2-(2-fluorophenyl)ethyl]-4-piperidinyl]phenylamino]- (9CI) (CA INDEX NAME)




RN 229478-82-4 CAPLUS

CN Benzamide, N-ethyl-4-[[1-[2-(2-fluorophenyl)ethyl]-4-piperidinyl](4-hydroxyphenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 229478-88-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-89-1 CAPLUS

CN Benzamide, N-ethyl-N-methyl-4-[(3-methylphenyl)[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-90-4 CAPLUS

CN Benzamide, 4-[(2,3-dimethoxyphenyl)[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-


10628309

4-piperidinyl]amino]-N-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 229478-91-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-92-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-94-8 CAPLUS


CN Benzamide, 4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl-
(9CI) (CA INDEX NAME)



RN 229478-95-9 CAPLUS


CN Pyrrolidine, 1-[4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)

10628309




RN 229478-96-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(2-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-98-2 CAPLUS


CN Benzamide, N,N-diethyl-4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-99-3 CAPLUS

CN Pyrrolidine, 1-[4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)


10628309




RN 229479-00-9 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-01-0 CAPLUS
CN Benzamide, 4-[(1-methyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229479-02-1 CAPLUS
CN Benzamide, N-ethyl-N-methyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-03-2 CAPLUS
CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)



RN 229479-04-3 CAPLUS


10628309

CN Morpholine, 4-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-05-4 CAPLUS

CN Piperidine, 1-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-06-5 CAPLUS

CN Pyrrolidine, 1-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-07-6 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229479-09-8 CAPLUS


CN Benzamide, 4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229479-10-1 CAPLUS

CN Benzamide, N-ethyl-4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-11-2 CAPLUS

CN Benzamide, 4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 229479-12-3 CAPLUS


CN Morpholine, 4-[4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-13-4 CAPLUS

CN Piperidine, 1-[4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)


10628309




RN 229479-14-5 CAPLUS
CN Pyrrolidine, 1-[4-[(3-methoxyphenyl)(1-methyl-4-piperidiny)amino]benzoyl]-
(9CI) (CA INDEX NAME)



RN 229479-15-6 CAPLUS
CN Benzamide, N,N-diethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidiny)amino]-
(9CI) (CA INDEX NAME)




RN 229479-16-7 CAPLUS
CN Benzamide, 4-[(3-fluorophenyl)(1-methyl-4-piperidiny)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229479-17-8 CAPLUS
CN Benzamide, N-ethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidiny)amino]-N-
methyl- (9CI) (CA INDEX NAME)

10628309




RN 229479-18-9 CAPLUS

CN Benzamide, 4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229479-19-0 CAPLUS

CN Morpholine, 4-[4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-21-4 CAPLUS


CN Piperidine, 1-[4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-22-5 CAPLUS

CN Pyrrolidine, 1-[4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)


10628309




RN 229479-23-6 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-24-7 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229479-25-8 CAPLUS
CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-26-9 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)phenylamino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



10628309


RN 229479-27-0 CAPLUS

CN Morpholine, 4-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-28-1 CAPLUS

CN Piperidine, 1-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-29-2 CAPLUS

CN Pyrrolidine, 1-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-30-5 CAPLUS


CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 229479-31-6 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 229479-32-7 CAPLUS
CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-33-8 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 229479-34-9 CAPLUS
CN Morpholine, 4-[4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-35-0 CAPLUS
CN Piperidine, 1-[4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-37-2 CAPLUS

10628309


CN Pyrrolidine, 1-[4-[(1-ethyl-4-piperidiny)(3-fluorophenyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)



RN 229479-39-4 CAPLUS
CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidiny)amino]-
, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 229478-91-5
CMF C26 H37 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 229479-40-7 CAPLUS
CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidiny)amino]-
, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229478-92-6
CMF C25 H35 N3 O2


10628309



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 229479-41-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl(1-propyl-4-piperidinyl)amino]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 229478-58-4

CMF C25 H35 N3 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 229479-45-2 CAPLUS

CN Benzamide, 4-[[3-(acetyloxy)phenyl](1-propyl-4-piperidinyl)amino]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:465974 CAPLUS

DN 137:47121

TI Preparation of N,N-diarylpiperidin-4-amines

IN Griffin, Andrew

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 28 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048108	A1	20020620	WO 2001-SE2780	20011213
	WO 2002048108	B1	20021010		
	WO 2002048108	C2	20040415		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2001046263	A1	20010628	WO 2000-SE2560	20001215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2002022879	A5	20020624	AU 2002-22879	20011213
	EP 1343762	A1	20030917	EP 2001-270530	20011213
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001016129	A	20031104	BR 2001-16129	20011213
	JP 2004515539	T2	20040527	JP 2002-549639	20011213
	US 2004068112	A1	20040408	US 2003-433719	20030604
	NO 2003002707	A	20030613	NO 2003-2707	20030613
PRAI	WO 2000-SE2560	W	20001215		
	SE 2001-1764	A	20010518		
	SE 1999-4675	A	19991220		
	WO 2001-SE2780	W	20011213		
OS	CASREACT 137:47121; MARPAT 137:47121				
AB	R7(CH ₂) _n ZNR ₁ R ₂ [R ₁ = (un)substituted Ph; R ₂ = (un)substituted Ph or -naphthyl; R ₇ = (un)substituted thienyl, -imidazolyl, -pyridinyl, -Ph, etc.; Z = (alkyl)piperidine-1,4-diyl] were prepared by 1-pot double arylation of R7(CH ₂) _n NH ₂ by aryl bromides in the presence of of a base, a Pd catalyst, and a phosphine ligand.				
IT	346664-66-2P				
	RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of N,N-diarylpiperidin-4-amines)				
RN	346664-66-2 CAPLUS				
CN	Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)				



10628309

IT 297750-45-9P 437986-94-2P 437986-95-3P


437986-96-4P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of N,N-diarylpiperidin-4-amines)


RN 297750-45-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 437986-94-2 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 437986-95-3 CAPLUS

CN Benzamide, 4-[(3-cyanophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 437986-96-4 CAPLUS

CN Benzoic acid, 4-[(3-cyanophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:730549 CAPLUS

10628309

DN 135:283207
TI Selective tropane ligands for the delta opioid receptor, their preparation
and their therapeutic use
IN Carroll, F. Ivy; Thomas, James B.; Mascarella, S. Wayne
PA Research Triangle Institute, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072303	A1	20011004	WO 2001-US8629	20010329
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-537668	A	20000329		
OS	MARPAT 135:283207				
GI					



AB The invention discloses substituted tropane derivs. I [Ra, Rb = H, alkyl, alkenyl, or Ra and Rb bonded; X = alkyl; Z = alkyl, OH, OR, CF₃, CN etc. ; R = alkyl, alkenyl, aryl, alkaryl; R1 = alkyl, alkenyl, alkaryl; n = 0-4; yr = 0-5; Z-substituted ring = 5 or 6 membered (hetero)aryl] which are selective for the delta opioid receptor. The invention also outlines the preparation of these derivs. e.g II (R1 = allyl) and their opioid receptor binding affinities. The inventive compds. may be used to treat disease states which are ameliorated by binding opioid receptors which include heroin addiction and pain (as analgesics).


IT **289468-26-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(delta opioid receptor ligands, preparation and therapeutic use)

RN 289468-26-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[(3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10628309




IT 289468-27-5P 289468-28-6P 289468-29-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(delta opioid receptor ligands, preparation and therapeutic use)

RN 289468-27-5 CAPLUS

CN Benzamide, 4-[[[(3-endo)-8-(2Z)-2-butenyl-8-azabicyclo[3.2.1]oct-3-yl](3-methoxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 289468-28-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[(3-endo)-8-(3-methyl-2-butenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 289468-29-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[(3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10628309



IT 364039-21-4 364039-22-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(delta opioid receptor ligands, preparation and therapeutic use)

RN 364039-21-4 CAPLUS

CN Benzamide, 4-[[[(3-endo)-8-(2Z)-2-butenyl-8-azabicyclo[3.2.1]oct-3-yl](3-hydroxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 364039-22-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[(3-endo)-8-(3-methyl-2-butenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 287720-99-4P 289468-31-1P 364039-20-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(delta opioid receptor ligands, preparation and therapeutic use)

RN 287720-99-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10628309



RN 289468-31-1 CAPLUS

CN Benzoic acid, 4-[(3-methoxyphenyl)((3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 364039-20-3 CAPLUS

CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-yl(3-methoxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:472786 CAPLUS

DN 135:76802


TI Preparation of 4-[3-(hydroxyphenyl)(4-piperidynyl)amino]-N,N-diethylbenzamides useful in the management of pain

IN Brown, William; Walpole, Christopher

10628309

PA Astrazeneca Ab, Swed.
 SO PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001046263	A1	20010628	WO 2000-SE2560	20001215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000016594	A	20020910	BR 2000-16594	20001215
EP 1242406	A1	20020925	EP 2000-989097	20001215
EP 1242406	B1	20040317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518136	T2	20030603	JP 2001-547172	20001215
EE 200200338	A	20031015	EE 2002-338	20001215
AT 261957	E	20040415	AT 2000-989097	20001215
NZ 519987	A	20040430	NZ 2000-519987	20001215
WO 2002048108	A1	20020620	WO 2001-SE2780	20011213
WO 2002048108	B1	20021010		
WO 2002048108	C2	20040415		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002022879	A5	20020624	AU 2002-22879	20011213
EP 1343762	A1	20030917	EP 2001-270530	20011213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016129	A	20031104	BR 2001-16129	20011213
JP 2004515539	T2	20040527	JP 2002-549639	20011213
BG 106807	A	20030331	BG 2002-106807	20020610
US 2003036552	A1	20030220	US 2002-149982	20020613
NO 2002002919	A	20020802	NO 2002-2919	20020618
US 2004068112	A1	20040408	US 2003-433719	20030604
NO 2003002707	A	20030613	NO 2003-2707	20030613
PRAI SE 1999-4675	A	19991220		
WO 2000-SE2560	W	20001215		
SE 2001-1764	A	20010518		
WO 2001-SE2780	W	20011213		
OS MARPAT 135:76802				
GI				



I

AB The title compds. [I; R1 = (un)substituted Ph, pyridinyl, thiophenyl, furanyl, imidazolyl, triazolyl; Ra, Rb = H, alkyl, NO₂, etc.] and their pharmaceutically acceptable salts, useful in therapy, in particular in the management of pain, were prepared E.g., a multi-step synthesis of I [R1 = Ph; Ra, Rb = H] was presented. Biol. data for compds. I were given.


IT 346664-69-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-[3-(4-piperidynyl)amino]-N,N-diethylbenzamides useful in the management of pain)

RN 346664-69-5 CAPLUS

CN Benzamide, 4-[[3-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




IT 297750-45-9P 346664-73-1P 346664-75-3P
 346664-79-7P 346664-80-0P 346664-82-2P
 346664-84-4P 346664-86-6P 346664-88-8P
 346664-90-2P 346664-92-4P 346664-94-6P
 346664-96-8P 346664-98-0P 346664-99-1P
 346665-01-8P 346665-03-0P 346665-05-2P
 346665-07-4P 346665-09-6P 346665-11-0P
 346665-13-2P 346665-15-4P 346665-17-6P
 346665-19-8P 346665-21-2P 346665-23-4P
 346665-25-6P 346665-27-8P 346665-29-0P
 346665-31-4P 346665-33-6P 346665-35-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[3-(4-piperidynyl)amino]-N,N-diethylbenzamides useful in the management of pain)

RN 297750-45-9 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346664-73-1 CAPLUS

CN Benzamide, 4-[(2-bromo-5-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)


10628309




RN 346664-75-3 CAPLUS
CN Benzamide, N,N-diethyl-4-[(5-hydroxy-2-iodophenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 346664-79-7 CAPLUS
CN Benzamide, 4-[(2,4-dibromo-5-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346664-80-0 CAPLUS
CN Benzamide, 4-[(2-chloro-5-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346664-82-2 CAPLUS
CN Benzamide, N,N-diethyl-4-[(2-fluoro-5-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)


10628309




RN 346664-84-4 CAPLUS
CN Benzamide, 4-[(2-bromo-5-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 346664-86-6 CAPLUS
CN Benzamide, 4-[(2-chloro-5-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346664-88-8 CAPLUS
CN Benzamide, N,N-diethyl-4-[(2-fluoro-5-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346664-90-2 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-(3-furanylmethyl)-4-piperidinyl)(3-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)

10628309




RN 346664-92-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1-(2-furanylmethyl)-4-piperidinyl](3-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 346664-94-6 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[1-(3-thienylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 346664-96-8 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[1-(2-thienylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

10628309




RN 346664-98-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl](3-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 346664-99-1 CAPLUS


CN Benzamide, N,N-diethyl-4-[[1-(3-furanylmethyl)-4-piperidinyl](3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 346665-01-8 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(3-thienylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

10628309




RN 346665-03-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(5-methoxy-2-methylphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346665-05-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(5-hydroxy-2-methylphenyl)[1-[(4-trifluoromethyl)phenyl]methyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346665-07-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(4-iodophenyl)methyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




10628309


RN 346665-09-6 CAPLUS
CN Benzamide, 4-[[[1-[(4-bromophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346665-11-0 CAPLUS
CN Benzamide, 4-[[[1-[(4-chlorophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346665-13-2 CAPLUS
CN Benzamide, N,N-diethyl-4-[[[1-[(4-fluorophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 346665-15-4 CAPLUS
CN Benzamide, 4-[[[1-[(2,4-dichlorophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 346665-17-6 CAPLUS
CN Benzamide, N,N-diethyl-4-[[[1-[(3-fluorophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 346665-19-8 CAPLUS
CN Benzamide, N,N-diethyl-4-[[[1-[(2-fluorophenyl)methyl]-4-piperidinyl](3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)

10628309




RN 346665-21-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(4-methylphenyl)methyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346665-23-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1-(2-furanylmethyl)-4-piperidinyl](3-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)




RN 346665-25-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(2-thienylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 346665-27-8 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(1H-imidazol-2-ylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



10628309


RN 346665-29-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(2-pyridinylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346665-31-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(1H-imidazol-4-ylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346665-33-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(4-pyridinylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 346665-35-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



IT 346665-37-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-[(3-hydroxyphenyl)(4-piperidynyl)amino]-N,N-diethylbenzamides useful in the management of pain)


RN 346665-37-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


10628309

CRN 297750-45-9
CME C29 H35 N3 O2



CM 2

CRN 76-05-1
CME C2 H F3 O2




IT 346664-66-2P 346664-67-3P 346664-71-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-[3-hydroxyphenyl]-(4-piperidynyl)amino]-N,N-diethylbenzamides useful in the management of pain)


RN 346664-66-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 346664-67-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)-4-piperidinylamino]- (9CI) (CA INDEX NAME)



RN 346664-71-9 CAPLUS


CN Benzamide, 4-[[2-bromo-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl][1-(phenylmethyl)-4-piperidinyl]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:472716 CAPLUS
DN 135:76801
TI Preparation of 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid
derivatives as delta-opioid receptor modulators
IN Carson, John R.; Boyd, Robert E.; Neilson, Lou Anne
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046191	A1	20010628	WO 2000-US33055	20001204
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6306876	B1	20011023	US 2000-728972	20001204
EP 1242421	A1	20020925	EP 2000-983946	20001204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003518119	T2	20030603	JP 2001-547101	20001204
PRAI US 1999-171422P	P	19991222		
US 2000-728972	A	20001204		
WO 2000-US33055	W	20001204		
OS MARPAT 135:76801				
GI				



AB 4-[Aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivs. I [R1 = alkyl, alkenyl, cycloalkyl, etc.; R2, R3 = H, alkyl, = (un)substituted Ph, etc.; X = S, O; Z = N, O; n = 0, 1; Ar = Ph, 1-naphthyl, 2-naphthyl; R4 = OH, halo, alkyl, CF3, etc.], delta-opioid receptor modulators and useful as analgesics, were prepared E.g. a solution of 8-methyl-N-phenyl-endo-8-azabicyclo[3.2.1]octan-3-amine, N,N-diethyl-4-bromobenzamide, tris(dibenzylideneacetone)dipalladium(0), tri-tert-butylphosphine, and sodium tert-butoxide in dry toluene was heated at about 110°C under argon in a pressure vessel for about 16 h. to give N,N-diethyl-4-

10628309

[phenyl(endo-8-methyl-8-azabicyclo[3.2.1]octan-3-yl)amino]benzamide
isolated as 1:1 fumarate salt.


IT 287721-06-6P 287721-10-2P 346708-40-5P
347888-67-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivs. as delta-opioid receptor modulators)

RN 287721-06-6 CAPLUS

CN Benzoic acid, 4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287721-10-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[[[(3-exo)-8-(3-methyl-2-butenyl)-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 346708-40-5 CAPLUS

CN Benzoic acid, 4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 347888-67-9 CAPLUS

CN Benzamide, 4-[[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




IT 287720-74-5P 287720-78-9P 287720-81-4P
 287720-83-6P 287720-85-8P 287720-86-9P
 287720-88-1P 287720-90-5P 287720-94-9P
 287720-96-1P 287720-97-2P 287720-98-3P
 287721-03-3P 287721-07-7P 287721-08-8P
 287721-09-9P 287721-11-3P 287721-13-5P
 287721-15-7P 287721-16-8P 287729-25-3P
 287729-26-4P 287729-27-5P 287729-28-6P
 287729-29-7P 346708-06-3P 346708-07-4P
 346708-08-5P 346708-11-0P 346708-12-1P
 346708-13-2P 346708-14-3P 346708-16-5P
 346708-17-6P 346708-24-5P 346708-26-7P
 346708-28-9P 346708-29-0P 346708-41-6P
 346708-42-7P 346708-43-8P 346708-45-0P
 347888-66-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivs. as delta-opioid receptor modulators)

RN 287720-74-5 CAPLUS

CN Benzamide, 4-[[[(3-endo)-8-(1,3-benzodioxol-5-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-78-9 CAPLUS

CN Benzamide, N-ethyl-N-(2-methyl-2-propenyl)-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 287720-81-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[(3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

10628309


Relative stereochemistry.



RN 287720-83-6 CAPLUS

CN Benzamide, N-methyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-N-propyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-85-8 CAPLUS

CN Benzamide, 4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-86-9 CAPLUS

CN Benzamide, N-ethyl-N-methyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 287720-88-1 CAPLUS

CN Benzamide, N-butyl-N-ethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.

10628309

CM 1

CRN 287721-12-4
CMF C30 H43 N3 O


Relative stereochemistry.



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 346708-17-6 CAPLUS
CN Benamide, N,N-diethyl-4-[[[(3-exo)-8-heptyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 346708-24-5 CAPLUS
CN Benzoic acid, 4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 287721-05-5
CMF C21 H24 N2 O2

Relative stereochemistry.




CM 2

CRN 76-05-1

10628309

CMF C2 H F3 O2



RN 346708-26-7 CAPLUS


CN Benzamide, N,N-dimethyl-4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 287721-02-2

CMF C23 H29 N3 O


Relative stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 346708-28-9 CAPLUS


CN Pyrrolidine, 1-[4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]benzoyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 287721-01-1

CMF C25 H31 N3 O

Relative stereochemistry.




CM 2

CRN 76-05-1

10628309


CMF C2 H F3 O2



RN 346708-29-0 CAPLUS

CN Benzamide, N-methyl-4-[[{(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl}phenylamino]-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 346708-41-6 CAPLUS

CN Benzoic acid, 4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl


RN 346708-42-7 CAPLUS

CN Benzamide, N,N-dimethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 287721-00-0
CMF C30 H35 N3 O

Relative stereochemistry.




CM 2

10628309


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 346708-43-8 CAPLUS
CN Benzamide, N-butyl-N-methyl-4-(phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 346708-45-0 CAPLUS
CN Benzenecarbothioamide, N,N-diethyl-4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 346708-44-9
CMF C25 H33 N3 S

Relative stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 347888-66-8 CAPLUS
CN Benzamide, N,N-diethyl-4-[[[(3-endo)-8-hexyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.

10628309



IT 287720-73-4P 287720-75-6P 287720-92-7P


287721-00-0P 287721-05-5P 287729-31-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivs. as delta-opioid receptor modulators)

RN 287720-73-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-75-6 CAPLUS

CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-ylphenylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-92-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 287721-00-0 CAPLUS

CN Benzamide, N,N-dimethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

10628309


Relative stereochemistry.



RN 287721-05-5 CAPLUS

CN Benzoic acid, 4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287729-31-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:311845 CAPLUS

DN 135:77092

TI Lead development of SL-3111; exploration of a second generation of non-peptide peptide mimetics for potent and selective δ -opioid receptor agonists

AU Okayama, Toru; Wei, Hongbing; Davis, Peg; Porreca, Frank; Yamamura, Henry I.; Hruby, Victor J.

CS Department of Chemistry, University of Arizona, Tucson, AZ, 85721, USA

SO Peptide Science (2001), Volume Date 2000, 37th, 349-352

CODEN: PSCIFQ; ISSN: 1344-7661

PB Japanese Peptide Society

DT Journal

LA English

AB A symposium report. SL-3111 [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] is a de novo designed non-peptide peptide mimetic agonist of the δ -opioid receptor. In this study, the scaffold piperazine was substituted to generate a diverse set of different conformations. The modification was made by adding or subtracting one carbon atom from the structure of SL-3111 followed by moving the nitrogen atom attached to the benzhydryl moiety out of the ring. A representative solid phase synthesis was also performed to seek the possibility of application to combinatorial chemical

IT 346693-26-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

10628309

(solid phase synthesis of SL-3111 analog)

RN 346693-26-3 CAPLUS

CN Phenol, 3-[[4-(1,1-dimethylethyl)phenyl][1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:146207 CAPLUS

DN 134:311264

TI Synthesis of aminophosphonate and amidophosphate derivatives of 2-indolinone

AU Muzaferova, E. A.; Akhmetova, G. Z.; Gurevich, P. A.

CS Kazan State Technological University, Kazan, Russia

SO Russian Journal of General Chemistry (Translation of Zhurnal Obshchei Khimii) (2000), 70(8), 1308-1309
CODEN: RJGCEK; ISSN: 1070-3632

PB MAIK Nauka/Interperiodica Publishing

DT Journal

LA English

OS CASREACT 134:311264

AB Reaction of indolinones with di-Et hydrogen phosphite and diisopropylamine in refluxing EtOH gave 46-59% 3-hydroxy-3-[(2-diisopropylamino-2-diethoxyphosphoryl)alkyl]-2-indolinones. The Pudovik reaction of isatin azomethines with pyrocatechol phosphite in DMF at 90° in the presence of Et3N gave 64-72% pyrocatecholophosphorylaminoindolinones.


IT 335354-88-6P 335354-89-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of indolinone aminophosphonates and amidophosphates)


RN 335354-88-6 CAPLUS

CN Benzenesulfonamide, 4-[(2,3-dihydro-2-oxo-1H-indol-3-yl)(2-oxido-1,3,2-benzodioxaphosphol-2-yl)amino]- (9CI) (CA INDEX NAME)



RN 335354-89-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)(2-oxido-1,3,2-benzodioxaphosphol-2-yl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:530560 CAPLUS
DN 133:261089
TI Synthesis and evaluation of 4-(N,N-diarylamino)piperidines with high selectivity to the δ -opioid receptor: a combined 3D-QSAR and ligand docking study
AU Podlogar, Brent L.; Poda, Gennady I.; Demeter, David A.; Zhang, Sui-Po; Carson, John R.; Neilson, Lou Anne; Reitz, Allen B.; Ferguson, David M.
CS Department of Chemistry, Bayer Research Center, West Haven, CT, 06516, USA
SO Drug Design and Discovery (2000), 17(1), 34-50
CODEN: DDDIEV; ISSN: 1055-9612
PB Harwood Academic Publishers
DT Journal
LA English
AB A series of 4-(N,N-diarylamino)piperidines are synthesized and evaluated for high affinity binding and selectivity to the δ -opioid receptor using a combination of 3D-QSAR and mol. docking techniques. Based on exptl. ligand binding data to both μ - and δ -opioid receptors, CoMFA fields are generated and applied to identify potential ligand modifications to further optimize lead compds. Mol. docking expts. to the δ -receptor are also reported that explain the CoMFA trends predicted as well as the differential binding and selectivity displayed by various compds. in the series. An anal. of the binding site model proposed indicates the piperidines take advantage of 3 key sites or binding domains within the δ -receptor. These include an aromatic pocket (approx. 1/3 into the receptor cavity), an aspartic acid residue (which serves as a docking point for the piperidinyl cationic amine) and a hydrophobic pocket at the extracellular boundary of the receptor cavity. Links are established between ligand modification and amino acid composition at these sites in μ and δ , providing new insight to the structural basis to binding and selectivity across the series and for related piperazines (i.e. SNC80 and BW373U86). Results are also presented that indicate δ - and μ -selectivity may be determined at alternate sites, suggesting opioid receptors may display multiple binding domains. The model is further supported by comparisons with opiate binding modes and site directed mutagenesis studies and is finally applied to suggest new strategies in ligand design.

IT 209902-09-0 209902-14-7 229477-67-2
229477-68-3 229477-69-4 229477-72-9
229477-73-0 229477-75-2 229477-76-3
229477-79-6 229477-82-1 229477-84-3
229477-88-7 229477-94-5 229477-95-6
229477-96-7 229477-97-8 229478-00-6
229478-03-9 229478-04-0 229478-05-1
229478-06-2 229478-07-3 229478-08-4
229478-09-5 229478-10-8 229478-11-9
229478-14-2 229478-15-3 229478-20-0
229478-21-1 229478-22-2 229478-23-3
229478-30-2 229478-37-9 229478-38-0
229478-39-1 229478-40-4 229478-41-5
229478-58-4 229478-63-1 229478-68-6
229478-94-8 229478-95-9 229478-96-0
229478-98-2 229479-00-9 229479-01-0
229479-02-1 229479-03-2 229479-15-6
229479-16-7 229479-23-6 229479-24-7
229479-25-8 229479-30-5 229479-31-6
229479-32-7 229479-33-8 229479-38-3
297750-36-8 297750-37-9 297750-38-0
297750-39-1 297750-40-4 297750-42-6


297750-43-7 297750-44-8 297750-45-9
 297750-46-0 297750-49-3 297750-50-6
 297750-51-7 297750-52-8 297750-53-9
 297750-54-0 297750-55-1 297750-56-2
 297750-57-3 297750-58-4 297750-59-5
 297750-60-8 297750-61-9 297750-62-0
 297750-63-1 297750-64-2 297750-65-3
 297750-66-4 297750-67-5 297750-68-6

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(synthesis and evaluation of (diarylamino)piperidines with high selectivity to δ -opioid receptor over μ -opioid receptor using combined 3D-QSAR and ligand docking study)


RN 209902-09-0 CAPLUS

CN Benzamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 209902-14-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-(2-phenylethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229477-67-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-(2-propenyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 229477-68-3 CAPLUS


CN Benzamide, 4-[[1-(cyclopropylmethyl)-4-piperidinyl]phenylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 229477-69-4 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(2-propenyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)

10628309




RN 229477-72-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-methyl-4-piperidiny)amino]-
(9CI) (CA INDEX NAME)




RN 229477-73-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidiny)(3-hydroxyphenyl)amino]-
(9CI) (CA INDEX NAME)




RN 229477-75-2 CAPLUS

CN Benzamide, 4-[(3-hydroxyphenyl)(1-methyl-4-piperidiny)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)



RN 229477-76-3 CAPLUS


CN Benzamide, 4-[(1-ethyl-4-piperidiny)(3-hydroxyphenyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)



RN 229477-79-6 CAPLUS


CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidiny)(3-hydroxyphenyl)amino]-
(9CI) (CA INDEX NAME)

10628309




RN 229477-82-1 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229477-84-3 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229477-88-7 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)(3-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 229477-94-5 CAPLUS


CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 229477-95-6 CAPLUS


CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229477-96-7 CAPLUS

CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyloxy)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229477-97-8 CAPLUS

CN Benzamide, N,N-dibutyl-4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyloxy)amino]- (9CI) (CA INDEX NAME)




RN 229478-00-6 CAPLUS

CN Benzamide, 4-[[4-(4-fluorophenyl)(1-propyl-4-piperidinyloxy)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-03-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[[2-(2-fluorophenyl)(1-propyl-4-piperidinyloxy)amino]- (9CI) (CA INDEX NAME)




10628309


RN 229478-04-0 CAPLUS
CN Benzamide, 4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229478-05-1 CAPLUS
CN Benzamide, 4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-06-2 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]-
(9CI) (CA INDEX NAME)



RN 229478-07-3 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny)amino]-N,N-diethyl-
(9CI) (CA INDEX NAME)




RN 229478-08-4 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229478-09-5 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny)amino]-N,N-


10628309

bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-10-8 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-11-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-14-2 CAPLUS


CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-15-3 CAPLUS


CN Benzamide, N,N-dibutyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)

10628309




RN 229478-20-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-21-1 CAPLUS

CN Benzamide, 4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229478-22-2 CAPLUS

CN Benzamide, N,N-bis(1-methylethyl)-4-[(3-methylphenyl)(1-propyl-4-
piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-23-3 CAPLUS


CN Benzamide, N,N-dibutyl-4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



10628309


RN 229478-30-2 CAPLUS

CN Benzamide, 4-[(2,3-dimethylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-37-9 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethoxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-38-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-39-1 CAPLUS


CN Benzamide, 4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229478-40-4 CAPLUS


CN Benzamide, N,N-bis(1-methylethyl)-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)

10628309




RN 229478-41-5 CAPLUS

CN Benzamide, N,N-dibutyl-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-58-4 CAPLUS

CN Benzamide, N,N-diethyl-4-(phenyl(1-propyl-4-piperidinyl)amino)- (9CI) (CA INDEX NAME)



RN 229478-63-1 CAPLUS


CN Benzamide, 4-[(1-naphthalenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-68-6 CAPLUS

CN Benzamide, 4-[(2,3-dihydro-1H-inden-5-yl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 229478-94-8 CAPLUS
CN Benzamide, 4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl-
(9CI) (CA INDEX NAME)



RN 229478-95-9 CAPLUS
CN Pyrrolidine, 1-[4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)




RN 229478-96-0 CAPLUS
CN Benzamide, N,N-diethyl-4-[(2-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-98-2 CAPLUS


10628309

CN Benzamide, N,N-diethyl-4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229479-00-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA
INDEX NAME)




RN 229479-01-0 CAPLUS

CN Benzamide, 4-[(1-methyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI)
(CA INDEX NAME)




RN 229479-02-1 CAPLUS

CN Benzamide, N-ethyl-N-methyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI)
(CA INDEX NAME)



RN 229479-03-2 CAPLUS


CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-methyl-4-piperidinyl)phenylamino]-
(9CI) (CA INDEX NAME)



10628309


RN 229479-15-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229479-16-7 CAPLUS

CN Benzamide, 4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229479-23-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]- (9CI) (CA
INDEX NAME)




RN 229479-24-7 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI) (CA
INDEX NAME)



RN 229479-25-8 CAPLUS

CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]-N-methyl- (9CI)
(CA INDEX NAME)




RN 229479-30-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-


10628309

(9CI) (CA INDEX NAME)




RN 229479-31-6 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229479-32-7 CAPLUS

CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N-methyl-
(9CI) (CA INDEX NAME)




RN 229479-33-8 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-bis(1-methylethyl)-
(9CI) (CA INDEX NAME)



RN 229479-38-3 CAPLUS


CN Benzamide, 4-[[3-(acetyloxy)phenyl](1-propyl-4-piperidinyl)amino]-N,N-diethyl-
(9CI) (CA INDEX NAME)



10628309


RN 297750-36-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[(2-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 297750-37-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)(5,6,7,8-tetrahydro-1-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 297750-38-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)-3-pyridinylamino]-
(9CI) (CA INDEX NAME)



RN 297750-39-1 CAPLUS


CN Benzamide, N,N-diethyl-4-[1H-indol-4-yl(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 297750-40-4 CAPLUS


10628309

CN Benzamide, N,N-diethyl-4-[[3-[(methylsulfonyl)amino]phenyl](1-propyl-4-piperidiny]amino]- (9CI) (CA INDEX NAME)




RN 297750-42-6 CAPLUS

CN Benzamide, 4-[[3-(acetylamino)phenyl](1-propyl-4-piperidiny]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 297750-43-7 CAPLUS

CN Benzamide, 4-[[3-(aminophenyl)(1-propyl-4-piperidiny]amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 297750-44-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[[1-(2-propenyl)-4-piperidiny][4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 297750-45-9 CAPLUS


CN Benzamide, N,N-diethyl-4-[[3-(hydroxyphenyl)[1-(phenylmethyl)-4-piperidiny]amino]- (9CI) (CA INDEX NAME)



10628309


RN 297750-46-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidiny)(4-hydroxyphenyl)amino]-
(9CI) (CA INDEX NAME)




RN 297750-49-3 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)-4-piperidinylamino]- (9CI)
(CA INDEX NAME)




RN 297750-50-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[4-piperidinyl[4-(trifluoromethyl)phenyl]amino]-
(9CI) (CA INDEX NAME)




RN 297750-51-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(1-methylethyl)-4-
piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 297750-52-8 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[1-(2-phenylethyl)-4-
piperidinyl]amino]- (9CI) (CA INDEX NAME)



10628309


RN 297750-53-9 CAPLUS

CN Piperidine, 2,6-dimethyl-1-[4-[phenyl(1-propyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 297750-54-0 CAPLUS

CN Piperidine, 1-[4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 297750-55-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(3-methyl-2-butenyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 297750-56-2 CAPLUS


CN Benzamide, N-ethyl-4-[(3-methoxyphenyl)[1-(2-phenylethyl)-4-piperidinyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 297750-57-3 CAPLUS


CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-hydroxyphenyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)

10628309




RN 297750-58-4 CAPLUS

CN Benzamide, 4-[(3-methoxyphenyl)[1-(2-phenylethyl)-4-piperidinyl]amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 297750-59-5 CAPLUS

CN Benzamide, 4-[(3-hydroxyphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 297750-60-8 CAPLUS


CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(4-hydroxyphenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 297750-61-9 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-methoxyphenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 297750-62-0 CAPLUS
CN Benzamide, 4-(1-naphthalenyl-4-piperidinylamino)-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 297750-63-1 CAPLUS
CN Benzamide, 4-(phenyl-4-piperidinylamino)-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 297750-64-2 CAPLUS
CN Benzamide, 4-[(1-(2-phenylethyl)-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 297750-65-3 CAPLUS
CN Benzamide, 4-[(1-(2-phenylethyl)-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



10628309


RN 297750-66-4 CAPLUS

CN Benzamide, N,N-dipropyl-4-[(1-propyl-4-piperidinyl)(5,6,7,8-tetrahydro-1-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 297750-67-5 CAPLUS

CN Benzamide, N,N-dipropyl-4-[(1-propyl-4-piperidinyl)-3-pyridinylamino]- (9CI) (CA INDEX NAME)



RN 297750-68-6 CAPLUS

CN Benzamide, 4-[1,3-benzodioxol-4-yl(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



IT 229478-91-5P


RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)

(synthesis and evaluation of (diaryl amino)piperidines with high selectivity to δ -opioid receptor over μ -opioid receptor using combined 3D-QSAR and ligand docking study)

RN 229478-91-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)

10628309




IT 229478-92-6P 229479-39-4P 229479-40-7P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(synthesis and evaluation of (diaryl amino)piperidines with high selectivity to δ -opioid receptor over μ -opioid receptor using combined 3D-QSAR and ligand docking study)

RN 229478-92-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229479-39-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 229478-91-5

CME C26 H37 N3 O2




CM 2

CRN 110-17-8

CME C4 H4 O4

Double bond geometry as shown.




RN 229479-40-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]-, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 229478-92-6


CME C25 H35 N3 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:419974 CAPLUS
 DN 133:193302
 TI 4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity
 AU Thomas, James B.; Atkinson, Robert N.; Rothman, Richard B.; Burgess, Jason P.; Mascarella, S. Wayne; Dersch, Christina M.; Xu, Heng; Carroll, F. Ivy
 CS Chemistry and Life Sciences, Research Triangle Institute, Research Triangle Park, NC, 27709, USA
 SO Bioorganic & Medicinal Chemistry Letters (2000), 10(11), 1281-1284
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 GI




I

AB The tropane derived compds., 4-[(8-alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides I (R = allyl, cis-crotyl, prenyl, R1 = Me; R = allyl, R1 = H), were synthesized and found to have high affinity and selectivity for the δ receptor. I are structurally similar to the full agonist (-)-RTI-5989-54; yet, efficacy studies for compds. in this series I reveal greatly diminished agonist activity as well as antagonism not found in piperidine-based compds. like (-)-RTI-5989-54.
 IT **289468-26-4P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 4-[(8-alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides as high affinity, selective ligands for delta opioid receptor illustrate factors important to antagonist activity)
 RN 289468-26-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)((3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl)amino]- (9CI) (CA INDEX NAME)

10628309

Relative stereochemistry.



IT 289468-27-5P 289468-28-6P 289468-29-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 4-[(8-alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides as high affinity, selective ligands for delta opioid receptor illustrate factors important to antagonist activity)

RN 289468-27-5 CAPLUS

CN Benzamide, 4-[[[(3-endo)-8-(2Z)-2-butenyl-8-azabicyclo[3.2.1]oct-3-yl](3-methoxyphenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 289468-28-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[(3-endo)-8-(3-methyl-2-butenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 289468-29-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[(3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

10628309

Relative stereochemistry.



IT 287720-99-4P 289468-31-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 4-[(8-alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-N,N-diethylbenzamides as high affinity, selective ligands for delta opioid receptor illustrate factors important to antagonist activity)

RN 287720-99-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 289468-31-1 CAPLUS

CN Benzoic acid, 4-[(3-methoxyphenyl)[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:379678 CAPLUS
 DN 133:144474
 TI Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists
 AU Boyd, Robert E.; Carson, John R.; Codd, Ellen E.; Gauthier, A. Diane; Neilson, Lou Anne; Zhang, Sui-Po
 CS Drug Discovery, R. W. Johnson Pharmaceutical Research Institute, Philadelphia, PA, 19477, USA
 SO Bioorganic & Medicinal Chemistry Letters (2000), 10(10), 1109-1111
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB A series of 4-diarylaminotropanes has been prepared Both endo and exo diastereomeric forms bound to the delta opioid receptor but the endo isomers were more potent and selective vs. the μ opioid receptor than the exo isomers. The most potent delta opioid agonist exhibited a delta opioid K_i of 0.2 nM and was 860-fold selective over μ .
 IT 229477-67-2 287720-73-4 287720-74-5
 287720-75-6 287720-76-7 287720-77-8
 287720-78-9 287720-79-0 287720-81-4
 287720-83-6 287720-85-8 287720-86-9
 287720-88-1 287720-90-5 287720-92-7
 287720-94-9 287720-95-0 287720-96-1
 287720-97-2 287720-98-3 287720-99-4
 287721-00-0 287721-01-1 287721-02-2
 287721-03-3 287721-04-4 287721-05-5
 287721-06-6 287721-07-7 287721-08-8
 287721-09-9 287721-10-2 287721-11-3
 287721-12-4 287721-13-5 287721-14-6
 287721-15-7 287721-16-8 287729-25-3
 287729-26-4 287729-27-5 287729-28-6
 287729-29-7 287729-31-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists)
 RN 229477-67-2 CAPLUS
 CN Benzamide, N,N-diethyl-4-[phenyl[1-(2-propenyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 287720-73-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-74-5 CAPLUS
 CN Benzamide, 4-[[[(3-endo)-8-(1,3-benzodioxol-5-ylmethyl)-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309


Relative stereochemistry.



RN 287720-75-6 CAPLUS

CN Benzamide, 4-[(3-endo)-8-azabicyclo[3.2.1]oct-3-ylphenylamino]-N,N-diethyl-
(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-76-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[(3-endo)-8-(2-propenyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-77-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-endo)-8-cyano-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 287720-78-9 CAPLUS

CN Benzamide, N-ethyl-N-(2-methyl-2-propenyl)-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)

10628309


Relative stereochemistry.



RN 287720-79-0 CAPLUS

CN Benzamide, N-ethyl-4-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-N-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-81-4 CAPLUS

CN Benzamide, N-methyl-4-[phenyl[(3-endo)-8-propyl-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-83-6 CAPLUS

CN Benzamide, N-methyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-N-propyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 287720-85-8 CAPLUS

CN Benzamide, 4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10628309



RN 287720-86-9 CAPLUS

CN Benzamide, N-ethyl-N-methyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-88-1 CAPLUS

CN Benzamide, N-butyl-N-ethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-90-5 CAPLUS

CN Benzamide, N-methyl-4-[[[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]-N-phenyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287720-92-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[(3-endo)-8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-yl]amino]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 287729-31-1 CAPLUS

CN Benzamide, N,N-diethyl-4-[[[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]phenylamino]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:460403 CAPLUS

DN 131:87826

TI Preparation of 4-[aryl(piperidin-4-yl)]aminobenzamides which bind to the delta-opioid receptor

IN Carson, John R.; Carmosin, Richard J.; Fitzpatrick, Louis J.; Reitz, Allen B.; Jetter, Michele C.

PA Ortho-Mcneil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 43 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933806	A1	19990708	WO 1998-US27350	19981223
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2316341	AA	19990708	CA 1998-2316341	19981223
AU 9920097	A1	19990719	AU 1999-20097	19981223
ZA 9811842	A	20000623	ZA 1998-11842	19981223
EP 1049676	A1	20001108	EP 1998-964871	19981223
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001527068	T2	20011225	JP 2000-526490	19981223
TW 476755	B	20020221	TW 1998-87121577	19990211
PRAI US 1997-68794P	P	19971224		
WO 1998-US27350	W	19981223		
OS MARPAT 131:87826				
GI				




AB 4-[Aryl(piperidin-4-yl)]aminobenzamides I [Ar = Ph, 1-naphthyl, 2-naphthyl; R1, R2 = H, alkyl, Ph, PhCH2, etc.; R3, R4, R5 = H, alkyl; R6 = H, alkyl, alkenyl, etc.; R7 = OH, halo, alkoxy, etc.; R8 = halo, alkyl, alkoxy, CF3], δ -opioid receptor agonists/antagonists, were prepared E.g., N,N-diethyl-4-[3-methoxyphenyl(1-propylpiperidin-4-yl)amino]benzamide fumarate was prepared As delta-opioid receptor agonists, such compds. are useful as analgesics.

IT 209902-03-4P 229477-67-2P 229477-68-3P
 229477-69-4P 229477-71-8P 229477-72-9P
 229477-73-0P 229477-74-1P 229477-75-2P
 229477-76-3P 229477-77-4P 229477-78-5P
 229477-79-6P 229477-80-9P 229477-81-0P
 229477-82-1P 229477-83-2P 229477-84-3P
 229477-85-4P 229477-86-5P 229477-87-6P
 229477-88-7P 229477-89-8P 229477-90-1P
 229477-91-2P 229477-92-3P 229477-93-4P
 229477-94-5P 229477-95-6P 229477-96-7P
 229477-97-8P 229477-98-9P 229478-00-6P
 229478-01-7P 229478-02-8P 229478-03-9P
 229478-04-0P 229478-05-1P 229478-06-2P
 229478-07-3P 229478-08-4P 229478-09-5P
 229478-10-8P 229478-11-9P 229478-13-1P
 229478-14-2P 229478-15-3P 229478-16-4P
 229478-17-5P 229478-18-6P 229478-19-7P
 229478-20-0P 229478-21-1P 229478-22-2P
 229478-23-3P 229478-25-5P 229478-26-6P
 229478-27-7P 229478-28-8P 229478-29-9P
 229478-30-2P 229478-31-3P 229478-32-4P
 229478-33-5P 229478-34-6P 229478-35-7P
 229478-37-9P 229478-38-0P 229478-39-1P
 229478-40-4P 229478-41-5P 229478-58-4P
 229478-63-1P 229478-64-2P 229478-66-4P
 229478-67-5P 229478-68-6P 229478-69-7P
 229478-70-0P 229478-72-2P 229478-73-3P
 229478-77-7P 229478-79-9P 229478-81-3P
 229478-82-4P 229478-84-6P 229478-85-7P
 229478-88-0P 229478-89-1P 229478-90-4P
 229478-91-5P 229478-92-6P 229478-93-7P
 229478-94-8P 229478-95-9P 229478-96-0P
 229478-98-2P 229478-99-3P 229479-00-9P
 229479-01-0P 229479-02-1P 229479-03-2P
 229479-04-3P 229479-05-4P 229479-06-5P
 229479-07-6P 229479-09-8P 229479-10-1P
 229479-11-2P 229479-12-3P 229479-13-4P
 229479-14-5P 229479-15-6P 229479-16-7P
 229479-17-8P 229479-18-9P 229479-19-0P
 229479-21-4P 229479-22-5P 229479-23-6P
 229479-24-7P 229479-25-8P 229479-26-9P
 229479-27-0P 229479-28-1P 229479-29-2P
 229479-30-5P 229479-31-6P 229479-32-7P
 229479-33-8P 229479-34-9P 229479-35-0P
 229479-37-2P 229479-38-3P 229479-39-4P
 229479-40-7P 229479-41-8P 229479-45-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and δ -opioid receptor binding of
 [aryl(piperidinyl)]aminobenzamides)


RN 209902-03-4 CAPLUS
 CN Benzamide, N,N-diethyl-4-[phenyl(1-(phenylmethyl)-4-piperidinyl)amino]-
 (9CI) (CA INDEX NAME)

10628309




RN 229477-67-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(phenyl[1-(2-propenyl)-4-piperidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 229477-68-3 CAPLUS

CN Benzamide, 4-[[1-(cyclopropylmethyl)-4-piperidinyl]phenylamino]-N,N-
diethyl- (9CI) (CA INDEX NAME)




RN 229477-69-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)[1-(2-propenyl)-4-
piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 229477-71-8 CAPLUS


CN Benzamide, 4-[[1-(cyclopropylmethyl)-4-piperidinyl](3-hydroxyphenyl)amino]-
N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229477-72-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)


10628309




RN 229477-73-0 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)(3-hydroxyphenyl)amino]-
(9CI) (CA INDEX NAME)




RN 229477-74-1 CAPLUS
CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-(2-phenylethyl)-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229477-75-2 CAPLUS
CN Benzamide, 4-[(3-hydroxyphenyl)(1-methyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229477-76-3 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-hydroxyphenyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229477-77-4 CAPLUS
CN Benzamide, 4-[(3-hydroxyphenyl)(1-(2-phenylethyl)-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 229477-78-5 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-hydroxyphenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229477-79-6 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)(3-hydroxyphenyl)amino]-
(9CI) (CA INDEX NAME)



RN 229477-80-9 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-hydroxyphenyl)[1-(2-phenylethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229477-81-0 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229477-82-1 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)


10628309




RN 229477-83-2 CAPLUS
CN Benzamide, N,N-dibutyl-4-[phenyl[1-(2-phenylethyl)-4-piperidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 229477-84-3 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229477-85-4 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-
(9CI) (CA INDEX NAME)




RN 229477-86-5 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-fluorophenyl)[1-(2-phenylethyl)-4-piperidinyl]amino]-
(9CI) (CA INDEX NAME)




RN 229477-87-6 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)

10628309




RN 229477-88-7 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(1-ethyl-4-piperidinyl)(3-methoxyphenyl)amino]-
(9CI) (CA INDEX NAME)




RN 229477-89-8 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(1-butyl-4-piperidinyl)(3-methoxyphenyl)amino]-
(9CI) (CA INDEX NAME)



RN 229477-90-1 CAPLUS


CN Benzamide, 4-[1,3-benzodioxol-5-yl(1-propyl-4-piperidinyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229477-91-2 CAPLUS

CN Benzamide, 4-[1,3-benzodioxol-5-yl(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 229477-92-3 CAPLUS
CN Benzamide, 4-[1,3-benzodioxol-5-yl(1-propyl-4-piperidiny)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 229477-93-4 CAPLUS
CN Benzamide, 4-[1,3-benzodioxol-5-yl(1-propyl-4-piperidiny)amino]-N,N-dibutyl- (9CI) (CA INDEX NAME)




RN 229477-94-5 CAPLUS
CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidiny)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229477-95-6 CAPLUS
CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidiny)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229477-96-7 CAPLUS

CN Benzamide, 4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229477-97-8 CAPLUS

CN Benzamide, N,N-dibutyl-4-[[3-(dimethylamino)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229477-98-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(4-fluorophenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-00-6 CAPLUS


CN Benzamide, 4-[(4-fluorophenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



10628309


RN 229478-01-7 CAPLUS

CN Benzamide, 4-[(4-fluorophenyl)(1-propyl-4-piperidiny)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-02-8 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(4-fluorophenyl)(1-propyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)




RN 229478-03-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]- (9CI) (CA INDEX NAME)




RN 229478-04-0 CAPLUS

CN Benzamide, 4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229478-05-1 CAPLUS


CN Benzamide, 4-[(2-fluorophenyl)(1-propyl-4-piperidiny)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-06-2 CAPLUS

10628309


CN Benzamide, N,N-dibutyl-4-[(2-fluorophenyl)(1-propyl-4-piperidiny1)amino]-
(9CI) (CA INDEX NAME)




RN 229478-07-3 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny1)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-08-4 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny1)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229478-09-5 CAPLUS
CN Benzamide, 4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny1)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-10-8 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(3-chloro-4-methoxyphenyl)(1-propyl-4-piperidiny1)amino]- (9CI) (CA INDEX NAME)




10628309


RN 229478-11-9 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-13-1 CAPLUS
CN Benzamide, N,N-dipropyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-14-2 CAPLUS
CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-15-3 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-16-4 CAPLUS
CN Benzamide, 4-[(3,5-dimethoxyphenyl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)

10628309




RN 229478-17-5 CAPLUS

CN Benzamide, 4-[(3,5-dimethoxyphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-18-6 CAPLUS

CN Benzamide, 4-[(3,5-dimethoxyphenyl)(1-propyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-19-7 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(3,5-dimethoxyphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-20-0 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



10628309


RN 229478-21-1 CAPLUS

CN Benzamide, 4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229478-22-2 CAPLUS

CN Benzamide, N,N-bis(1-methylethyl)-4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-23-3 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(3-methylphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-25-5 CAPLUS


CN Benzamide, N,N-diethyl-4-[(4-methylphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-26-6 CAPLUS

CN Benzamide, 4-[(4-methylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)


10628309




RN 229478-27-7 CAPLUS
CN Benzamide, N,N-bis(1-methylethyl)-4-[(4-methylphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-28-8 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(4-methylphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-29-9 CAPLUS
CN Benzamide, 4-[(2,3-dimethylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-30-2 CAPLUS
CN Benzamide, 4-[(2,3-dimethylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229478-31-3 CAPLUS

CN Benzamide, 4-[(2,3-dimethylphenyl)(1-propyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229478-32-4 CAPLUS

CN Benzamide, N,N-dibutyl-4-[(2,3-dimethylphenyl)(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-33-5 CAPLUS


CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethoxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-34-6 CAPLUS

CN Benzamide, N,N-dipropyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethoxy)phenyl]amino]- (9CI) (CA INDEX NAME)


10628309




RN 229478-35-7 CAPLUS
CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethoxy)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-37-9 CAPLUS
CN Benzamide, N,N-dibutyl-4-[(1-propyl-4-piperidinyl)[3-(trifluoromethoxy)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-38-0 CAPLUS
CN Benzamide, N,N-diethyl-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-39-1 CAPLUS
CN Benzamide, 4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229478-40-4 CAPLUS

CN Benzamide, N,N-bis(1-methylethyl)-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-41-5 CAPLUS

CN Benzamide, N,N-dibutyl-4-[[3-(methylthio)phenyl](1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-58-4 CAPLUS


CN Benzamide, N,N-diethyl-4-[phenyl(1-propyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-63-1 CAPLUS


CN Benzamide, 4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229478-64-2 CAPLUS

CN Benzamide, N,N-diethyl-4-[(1-propyl-4-piperidinyl)(5,6,7,8-tetrahydro-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)




RN 229478-66-4 CAPLUS

CN Benzamide, N,N-dipropyl-4-[(1-propyl-4-piperidinyl)(5,6,7,8-tetrahydro-2-naphthalenyl)amino]- (9CI) (CA INDEX NAME)



RN 229478-67-5 CAPLUS


CN Benzamide, 4-[(2,3-dihydro-1H-inden-5-yl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



10628309


RN 229478-68-6 CAPLUS

CN Benzamide, 4-[(2,3-dihydro-1H-inden-5-yl)(1-propyl-4-piperidinyl)amino]-
N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-69-7 CAPLUS

CN Benzamide, 4-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinyl]phenylamino]-
N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-70-0 CAPLUS

CN Benzamide, 4-[[1-[2-(3,4-dimethoxyphenyl)ethyl]-4-piperidinyl](3-
fluorophenyl)amino]-N,N-diethyl- (9CI) (CA INDEX NAME)



RN 229478-72-2 CAPLUS


CN Benzamide, 4-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-piperidinyl]phenylamino]-
N,N-diethyl- (9CI) (CA INDEX NAME)




RN 229478-73-3 CAPLUS

CN Benzamide, 4-[[1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-piperidinyl](3-
methoxyphenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)


10628309




RN 229478-77-7 CAPLUS
 CN Benzamide, N,N-diethyl-4-[phenyl[1-[2-(2-thienyl)ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-79-9 CAPLUS
 CN Benzamide, 4-[(2-fluorophenyl)[1-[2-(2-thienyl)ethyl]-4-piperidinyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229478-81-3 CAPLUS
 CN Benzamide, N,N-diethyl-4-[[1-[2-(2-fluorophenyl)ethyl]-4-piperidinyl]phenylamino]- (9CI) (CA INDEX NAME)




RN 229478-82-4 CAPLUS
 CN Benzamide, N-ethyl-4-[[1-[2-(2-fluorophenyl)ethyl]-4-piperidinyl](4-hydroxyphenyl)amino]-N-propyl- (9CI) (CA INDEX NAME)



RN 229478-84-6 CAPLUS


10628309

CN Benzamide, N,N-diethyl-4-[phenyl[1-[2-(3-pyridinyl)ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-85-7 CAPLUS

CN Benzamide, 4-[[3-(methylthio)phenyl][1-[2-(3-pyridinyl)ethyl]-4-piperidinyl]amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 229478-88-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 229478-89-1 CAPLUS

CN Benzamide, N-ethyl-N-methyl-4-[(3-methylphenyl)[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 229478-90-4 CAPLUS


CN Benzamide, 4-[(2,3-dimethoxyphenyl)[1-[2-[3-(trifluoromethyl)phenyl]ethyl]-4-piperidinyl]amino]-N-methyl-N-propyl- (9CI) (CA INDEX NAME)



10628309


RN 229478-91-5 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-92-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-93-7 CAPLUS

CN Benzamide, N-methyl-N-phenyl-4-[phenyl(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-94-8 CAPLUS


CN Benzamide, 4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]-N,N-diethyl-
(9CI) (CA INDEX NAME)



RN 229478-95-9 CAPLUS


CN Pyrrolidine, 1-[4-[(3-chlorophenyl)(1-propyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)

10628309




RN 229478-96-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[(2-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229478-98-2 CAPLUS


CN Benzamide, N,N-diethyl-4-[1-naphthalenyl(1-propyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)




RN 229478-99-3 CAPLUS

CN Pyrrolidine, 1-[4-[1-(1-naphthalenyl)(1-propyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)


10628309




RN 229479-00-9 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-01-0 CAPLUS
CN Benzamide, 4-[(1-methyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229479-02-1 CAPLUS
CN Benzamide, N-ethyl-N-methyl-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-03-2 CAPLUS
CN Benzamide, N,N-bis(1-methylethyl)-4-[(1-methyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)



RN 229479-04-3 CAPLUS


10628309

CN Morpholine, 4-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-05-4 CAPLUS

CN Piperidine, 1-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-06-5 CAPLUS

CN Pyrrolidine, 1-[4-[(1-methyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-07-6 CAPLUS


CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 229479-09-8 CAPLUS


CN Benzamide, 4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229479-10-1 CAPLUS

CN Benzamide, N-ethyl-4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-11-2 CAPLUS

CN Benzamide, 4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 229479-12-3 CAPLUS


CN Morpholine, 4-[4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-13-4 CAPLUS


CN Piperidine, 1-[4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)

10628309




RN 229479-14-5 CAPLUS

CN Pyrrolidine, 1-[4-[(3-methoxyphenyl)(1-methyl-4-piperidinyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)




RN 229479-15-6 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-
(9CI) (CA INDEX NAME)



RN 229479-16-7 CAPLUS


CN Benzamide, N-ethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-N,N-dipropyl-
(9CI) (CA INDEX NAME)




RN 229479-17-8 CAPLUS

CN Benzamide, N-ethyl-4-[(3-fluorophenyl)(1-methyl-4-piperidinyl)amino]-N-methyl-
(9CI) (CA INDEX NAME)


10628309




RN 229479-18-9 CAPLUS
CN Benzamide, 4-[[3-fluorophenyl](1-methyl-4-piperidinyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 229479-19-0 CAPLUS
CN Morpholine, 4-[[3-fluorophenyl](1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-21-4 CAPLUS
CN Piperidine, 1-[[4-[[3-fluorophenyl](1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-22-5 CAPLUS
CN Pyrrolidine, 1-[[4-[[3-fluorophenyl](1-methyl-4-piperidinyl)amino]benzoyl]- (9CI) (CA INDEX NAME)


10628309




RN 229479-23-6 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]- (9CI) (CA INDEX NAME)




RN 229479-24-7 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)phenylamino]-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 229479-25-8 CAPLUS
CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)phenylamino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-26-9 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)phenylamino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




10628309


RN 229479-27-0 CAPLUS
CN Morpholine, 4-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-28-1 CAPLUS
CN Piperidine, 1-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-29-2 CAPLUS
CN Pyrrolidine, 1-[4-[(1-ethyl-4-piperidinyl)phenylamino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-30-5 CAPLUS
CN Benzamide, N,N-diethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]- (9CI) (CA INDEX NAME)




RN 229479-31-6 CAPLUS
CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-dipropyl- (9CI) (CA INDEX NAME)

10628309




RN 229479-32-7 CAPLUS

CN Benzamide, N-ethyl-4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 229479-33-8 CAPLUS

CN Benzamide, 4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 229479-34-9 CAPLUS

CN Morpholine, 4-[4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)



RN 229479-35-0 CAPLUS


CN Piperidine, 1-[4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 229479-37-2 CAPLUS

10628309

CN Pyrrolidine, 1-[4-[(1-ethyl-4-piperidinyl)(3-fluorophenyl)amino]benzoyl]-
(9CI) (CA INDEX NAME)




RN 229479-38-3 CAPLUS
CN Benzamide, 4-[[3-(acetyloxy)phenyl](1-propyl-4-piperidinyl)amino]-N,N-
diethyl- (9CI) (CA INDEX NAME)



RN 229479-39-4 CAPLUS
CN Benzamide, N,N-diethyl-4-[(3-methoxyphenyl)(1-propyl-4-piperidinyl)amino]-
, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 229478-91-5
CMF C26 H37 N3 O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



10628309


RN 229479-40-7 CAPLUS

CN Benzamide, N,N-diethyl-4-[(3-hydroxyphenyl)(1-propyl-4-piperidinyl)amino]-
, ethanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 229478-92-6


CMF C25 H35 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 229479-41-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl(1-propyl-4-piperidinyl)amino]-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 229478-58-4

CMF C25 H35 N3 O




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 229479-45-2 CAPLUS

CN Benzamide, 4-[[3-(acetyloxy)phenyl](1-propyl-4-piperidinyl)amino]-N,N-
diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:479507 CAPLUS
DN 129:108996
TI Preparation of 4-aminopiperidines with analgesic effect
IN Pelcman, Benjamin; Roberts, Edward
PA Astra Pharma Inc., Can.; Astra Aktiebolag (Publ)
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

This apply

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9828270	A1	19980702	WO 1997-SE2051	19971209
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1428821	A1	20040616	EP 2004-2901	19970109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK				
ZA 9711049	A	19980622	ZA 1997-11049	19971209
AU 9853513	A1	19980717	AU 1998-53513	19971209
AU 738002	B2	20010906		
EP 946510	A1	19991006	EP 1997-950539	19971209
EP 946510	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1241178	A	20000112	CN 1997-180837	19971209
BR 9713785	A	20000208	BR 1997-13785	19971209
EE 9900261	A	20000215	EE 1999-261	19971209
EE 3966	B1	20030217		
NZ 336028	A	20010330	NZ 1997-336028	19971209
JP 2001507021	T2	20010529	JP 1998-528670	19971209
RU 2193030	C2	20021120	RU 1999-115746	19971209
SK 283300	B6	20030502	SK 1999-763	19971209
AT 266638	E	20040515	AT 1997-950539	19971209
US 6153626	A	20001128	US 1998-29468	19980303
MX 9905669	A	20000131	MX 1999-5669	19990617
NO 9903023	A	19990812	NO 1999-3023	19990618
US 6399635	B1	20020604	US 2000-645565	20000825
US 2003055045	A1	20030320	US 2002-121683	20020415
US 6710179	B2	20040323		
PRAI SE 1996-4786	A	19961220		
WO 1997-SE2051	W	19971209		
US 1998-29468	A3	19980303		
US 2000-645565	A3	20000825		
OS MARPAT 129:108996				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; m = 0-1; n = 0-2; R1 = H, C1-6 alkyl, C3-8 cycloalkyl, etc.; A = II, III, etc. (wherein R6-R9 = R1; Z1, Z2 = H, Me, halo, etc.); B = (un)substituted aromatic, heteroarom., etc.], useful in therapy, in particular in the management of pain, treatment of gastrointestinal disorders, spinal injuries, sympathetic nervous system disorders, and, when isotopically labeled, as diagnostic agent (no data), were prepared. Thus, reaction of 4-[N-(1-benzylpiperidin-4-yl)amino]-N,N-diethylbenzamide with tri-1-naphthylbismuth in the presence of Cu(OAc)₂ in PhMe afforded 83% IV.

IT 209902-03-4P 209902-08-9P 209902-09-0P


209902-33-0P 209902-38-5P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-aminopiperidines with analgesic effect)


RN 209902-03-4 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




RN 209902-08-9 CAPLUS

CN Benzamide, N,N-diethyl-4-[2-naphthalenyl[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 209902-09-0 CAPLUS


CN Benzamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)




RN 209902-33-0 CAPLUS

CN Benzamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-3-pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)


10628309



RN 209902-38-5 CAPLUS
CN Benzenesulfonamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)




IT 209902-04-5P 209902-05-6P 209902-06-7P
209902-07-8P 209902-10-3P 209902-11-4P
209902-12-5P 209902-13-6P 209902-14-7P
209902-34-1P 209902-35-2P 209902-36-3P
209902-39-6P 209902-40-9P 209902-41-0P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-aminopiperidines with analgesic effect)
RN 209902-04-5 CAPLUS
CN Benzamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-4-piperidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 209902-05-6 CAPLUS
CN Benzamide, N,N-diethyl-4-[(4-methylphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 209902-06-7 CAPLUS

10628309


CN Benzamide, N,N-diethyl-4-[(4-methylphenyl)[1-(phenylmethyl)-4-piperidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 209902-07-8 CAPLUS

CN Benzamide, N,N-diethyl-4-[1-naphthalenyl[1-(phenylmethyl)-4-piperidinyl]amino]- (9CI) (CA INDEX NAME)



RN 209902-10-3 CAPLUS

CN Benzamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 209902-11-4 CAPLUS

CN Benzamide, N,N-diethyl-4-(1-naphthalenyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)

10628309




RN 209902-12-5 CAPLUS
CN Benzamide, N,N-diethyl-4-(2-naphthalenyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 209902-13-6 CAPLUS
CN Benzamide, N,N-diethyl-4-(2-naphthalenyl-4-piperidinylamino)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 209902-12-5
CMF C26 H31 N3 O



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 209902-14-7 CAPLUS


10628309

CN Benzamide, N,N-diethyl-4-[phenyl[1-(2-phenylethyl)-4-piperidinyl]amino]-
(9CI) (CA INDEX NAME)



RN 209902-34-1 CAPLUS


CN Benzamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-3-pyrrolidinyl]amino]-,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 209902-35-2 CAPLUS


CN Benzamide, N,N-diethyl-4-(phenyl-3-pyrrolidinylamino)- (9CI) (CA INDEX
NAME)



RN 209902-36-3 CAPLUS

CN Benzamide, N,N-diethyl-4-(phenyl-3-pyrrolidinylamino)-, dihydrochloride
(9CI) (CA INDEX NAME)

10628309



● 2 HCl


RN 209902-39-6 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-[phenyl[1-(phenylmethyl)-4-piperidinyl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209902-38-5


CMF C28 H35 N3 O2 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 209902-40-9 CAPLUS

CN Benzenesulfonamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 209902-41-0 CAPLUS


CN Benzenesulfonamide, N,N-diethyl-4-(phenyl-4-piperidinylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 209902-40-9

10628309


CMF C21 H29 N3 O2 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1982:53221 CAPLUS

DN 96:53221

TI Curing agents for epoxy resins

PA Matsushita Electric Works, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 5 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56118415	A2	19810917	JP 1980-21889	19800222
PRAI	JP 1980-21889		19800222		
GI					




AB A curing agent for epoxy resins is a diamine I (Z = divalent group containing ≥ 1 aromatic or heterocyclic ring; R, R1 = H, alkyl; the phenol ring may be substituted by alkyl, OH, or halogen; the 2 substituents on Z need not be the same). Thus, 0.335 mol 4,4'-diaminodiphenylmethane [101-77-9] and 1.34 mol N-(p-hydroxyphenyl)maleimide (II) [7300-91-6] were heated at 180-220° for 60 min to obtain a dark brown curing agent [80451-45-2] with mol. weight 950, which was soluble in N-methyl-2-pyrrolidone, Me2SO, DMF, dioxane, MeCOEt, and MeOH. A mixture of 100 g Epikote 154 [63939-13-9] and 125.5 g of the curing agent was heated at 170° for 2 h and at 200° for 3 h. The product had Tg 255° and gel time (50% acetone solution, 160°) 7.0 min. Epikote 828 containing a reaction product of 3,3'-diaminobenzidine and II had Tg 250° and gel time 3.5 min.

IT 80451-45-2

RL: MOA (Modifier or additive use); USES (Uses)
(crosslinking agents, for epoxy resins, preparation of)

RN 80451-45-2 CAPLUS

CN 2,5-Pyrrolidinedione, 3,3',3'',3'''-[methylenebis(4,1-phenylenenitrilo)]tetrakis[1-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1961:116079 CAPLUS

DN 55:116079

OREF 55:21792e-i

TI Ultraviolet absorption of maleic and fumaric arylmonoamides and N-arylaspartic arylimides

AU Grammaticakis, Panos

SO Compt. rend. (1961), 252, 556-8

DT Journal

LA Unavailable

AB Series of maleic and fumaric arylmonoamides and N-arylaspartic arylimides were prepared and their ultraviolet spectra examined. The compounds and their m.p. (slow and instantaneous m.p. on the Maquenne block) were: maleic arylmonoamides, aryl = phenyl 220°, 232°; tolyl o- 121°, 126°, m- 172°, 186°, p- 213°, 217°; 2,6-dimethylphenyl 178°, 186°; 2,4,6-trimethylphenyl 164°, -; chlorophenyl o- 137°, 140°, m- 209°, 222°, p- 212°, 225°; methoxyphenyl o- 147°, 152°, m- 168°, 172°, p- 195°, 212°; nitrophenyl o- 157°, 166°, m- 207°, 233°, p- 206°, 232°; and carboxyphenyl o- 205°, 228° (decompose), m- 245°, 280° (decompose), p- 252°, 285° (decompose); fumaric arylmonoamides, aryl = phenyl 246°, 247°; tolyl o- 243°, 244°, m- 199-200°, -; 2,6-dimethylphenyl 267°, -; 2,4,6-trimethylphenyl 281°, -; chlorophenyl o- 247°, 249°, p- 279°, 280°; N-arylaspartic arylimides, aryl = phenyl, 215°, 216°; tolyl o- 129°, 148°, p- 214°, 218°; m-chlorophenyl 154°, 156°. The principal spectral relations found for the maleic arylmonoamides (anomalous ortho effect, steric effect, etc.) were identical to those determined previously for N-acylarylamines (CA 45, 7430h). Comparison of N-benzoylarylamines with the corresponding maleic arylmonoamide shows a displacement of the absorption of the latter toward the visible. Comparison of the spectra of RCONHAr, where R is MeCH:CH, Ph, or HO2CCH:CH, as in the maleic and fumaric arylmonoamides, shows the spectral conjugation effect of the free CO2H to be strong and to depend on the spectral type of the arylamine. Differences between the spectra of the maleic and fumaric arylmonoamides are slight, the fumaric showing a slight exaltation of the position and ϵ_{max} of the principal absorption band A. Spectra of the N-arylaspartic arylimides were found to be completely different from those of the corresponding maleic arylmonoamides, but related to those of the corresponding N-methylated arylamines.

IT 109558-25-0, Succinimide, 2-p-toluidino-N-p-tolyl- (spectrum of)

RN 109558-25-0 CAPLUS

CN Succinimide, 2-p-toluidino-N-p-tolyl- (6CI) (CA INDEX NAME)

10628309

